Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026)

Johnson & Johnson (JNJ) posted Non-Current Assets of $141.7 billion for Q1 2026, down 1.3% sequentially from $143.6 billion in Q4 2025, and up 16.05% YoY from $122.1 billion in Q1 2025.

Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026) Analysis & Trends

Johnson & Johnson (JNJ) has 18 years of Non-Current Assets data on file, last reported at $141.7 billion in Q1 2026.

  • Quarterly Non-Current Assets rose 16.05% year-over-year to $141.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $562.4 billion (up 13.7% YoY) and the FY2025 annual result came in at $143.6 billion, up 15.6% from the prior year.
  • Non-Current Assets retreated to $141.7 billion in Q1 2026 per JNJ's latest filing, from $143.6 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $143.6 billion in Q4 2025, with the low at $109.9 billion in Q4 2022.
  • Average Non-Current Assets over 5 years is $125.3 billion, with a median of $123.7 billion recorded in 2024.
  • Year-over-year, Non-Current Assets decreased 13.64% in 2023 and advanced 16.05% in 2026.
  • Johnson & Johnson's Non-Current Assets stood at $109.9 billion in 2022, then advanced by 3.8% to $114.1 billion in 2023, then gained by 8.9% to $124.2 billion in 2024, then increased by 15.6% to $143.6 billion in 2025, then slipped by 1.3% to $141.7 billion in 2026.
  • Business Quant data shows JNJ's Non-Current Assets at $141.7 billion in Q1 2026, $143.6 billion in Q4 2025, and $138.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 61.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 141.72 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 102.93 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 84.40 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 125.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 61.03 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 37.64 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 165.18 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 20.29 Bn

Historic Data

Download Data
DateValue
Mar 29, 2026 141.72 Bn
Dec 28, 2025 143.59 Bn
Sep 28, 2025 138.21 Bn
Jun 29, 2025 138.89 Bn
Mar 30, 2025 122.12 Bn
Dec 29, 2024 124.21 Bn
Sep 29, 2024 125.04 Bn
Jun 30, 2024 123.27 Bn
Mar 31, 2024 114.96 Bn
Dec 31, 2023 114.06 Bn
Oct 1, 2023 112.36 Bn
Jul 2, 2023 131.12 Bn
Apr 2, 2023 131.58 Bn
Jan 1, 2023 132.08 Bn
Oct 2, 2022 109.89 Bn
Jul 3, 2022 113.88 Bn
Apr 3, 2022 117.93 Bn
Jan 2, 2022 121.04 Bn
Oct 3, 2021 119.34 Bn
Jul 4, 2021 122.67 Bn